Further research has indicated that globulol inhibits PD-L1 expression by targeting the PAK4-pAKT-STAT3 axis, improves the immunosuppressive microenvironment of HCC, and enhances the pharmacological effects in combination with Tislelizumab.<h4>Conclusion</h4>These results suggest that Globulol can promote a microenvironment permissive to PD-1 blockade, thereby exerting anti-HCC activity. Here, STAT3 is linked to hepatocellular carcinoma.